SUPPRESTEM Consortium Led by Merus Receives $7.7 Million FP7 Grant From the

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Utrecht, The Netherlands, May 27, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has been granted funding from the European Union's FP7 program.

http://www.biospace.com/news_story.aspx?StoryID=298074&full=1